At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 127 enrolled
Drug / intervention
follicle stimulating hormonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Step-down Approach During Late Follicular Phase in Recombinant FSH-stimulation Dosage for IVF on Progesterone Level on the Day of Final Oocyte Maturation
In Brief
A Early Phase 1 clinical trial evaluating follicle stimulating hormone for Progesterone Resistance. Completed, enrolled 127 participants across 1 site.
Detailed Summary
Step-down approach and late follicular phase progesterone level
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgesterone Resistance
CountriesUnited Arab Emirates
CollaboratorsMerck Serono International SA
Timeline
Early Ph 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionFeb 2020
Study CompletionAug 2020
TodayJul 2026
First PostedNov 29, 2017
Enrollment StartNov 23, 2017
Primary CompletionFeb 12, 2020
Study CompletionAug 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.6 years ago
Interventions
follicle stimulating hormonedrug
Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged